Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.

Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check37 days agoChange DetectedThe page has been updated to include the term 'Multiple Myeloma' and a new revision number, while significant background information about a Phase 3 study has been removed.SummaryDifference34%
- Check44 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed the date 2025-03-25 while adding the date 2024-12-24.SummaryDifference0.4%
- Check51 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new posting date of March 25, 2025, replacing the previous estimated dates and version. This indicates a significant update in the content's accuracy and reliability.SummaryDifference0.3%
- Check80 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check102 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.